| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 18.243 | 12.267 | 335.302 | 162.697 | 0 | - | - | - | - |
| Total Income - EUR | - | 18.296 | 12.288 | 337.373 | 164.933 | 1.644 | - | - | - | - |
| Total Expenses - EUR | - | 15.395 | 13.304 | 392.106 | 162.872 | 3.242 | - | - | - | - |
| Gross Profit/Loss - EUR | - | 2.901 | -1.015 | -54.733 | 2.061 | -1.597 | - | - | - | - |
| Net Profit/Loss - EUR | - | 2.352 | -1.383 | -57.933 | 616 | -1.597 | - | - | - | - |
| Employees | - | 1 | 1 | 1 | 1 | 0 | - | - | - | - |
Check the financial reports for the company - Veral Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 489 | 336 | - | - | - | - |
| Current Assets | - | 23.317 | 8.270 | 49.933 | 27.228 | 27.334 | - | - | - | - |
| Inventories | - | 3.596 | 3.545 | 0 | 0 | 0 | - | - | - | - |
| Receivables | - | 2.585 | 2.052 | 44.542 | 27.226 | 26.766 | - | - | - | - |
| Cash | - | 17.136 | 2.674 | 5.391 | 2 | 568 | - | - | - | - |
| Shareholders Funds | - | 2.441 | 1.017 | -60.399 | -58.759 | -59.242 | - | - | - | - |
| Social Capital | - | 89 | 88 | 86 | 105 | 103 | - | - | - | - |
| Debts | - | 21.043 | 7.417 | 87.040 | 86.496 | 86.430 | - | - | - | - |
| Income in Advance | - | 0 | 0 | 23.292 | 0 | 565 | - | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4644 - 4644" | |||||||||
| CAEN Financial Year |
4644
|
|||||||||
Comments - Veral Pharma S.r.l.